Peter Altmaier (l), Federal Minister of Economics and Technology, and Ulrich Nu'baum (r), State Secretary in the Federal Ministry of Economics, take part in a press conference with Franz-Werner Haas (on screen), CEO of the biotech company Curevac, and the investor Hopp.

GSK, Ger­many push coro­n­avirus-fo­cused mR­NA play­er Cure­Vac's lat­est round to $640M

Af­ter court­ing some high-pro­file in­vestors, Cure­Vac has closed a whop­ping $640 mil­lion (€560 mil­lion) in its lat­est round.

The biotech an­nounced the fi­nanc­ing in a brief press re­lease, not­ing that pre­vi­ous­ly dis­closed in­vest­ments from the Ger­man fed­er­al gov­ern­ment and Glax­o­SmithK­line ac­count­ed for $514 mil­lion of the to­tal. Qatar In­vest­ment Au­thor­i­ty and oth­er ex­ist­ing as well as new in­vestors con­tributed the rest.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.